<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40958</article-id><article-id pub-id-type="doi">10.7554/eLife.40958</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>UBE2G1 governs the destruction of cereblon neomorphic substrates</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-118939"><name><surname>Lu</surname><given-names>Gang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2138-1522</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-119418"><name><surname>Weng</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-119438"><name><surname>Matyskiela</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-119421"><name><surname>Zheng</surname><given-names>Xinde</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-119422"><name><surname>Fang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-119423"><name><surname>Wood</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-119424"><name><surname>Surka</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-119425"><name><surname>Mizukoshi</surname><given-names>Reina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-119426"><name><surname>Lu</surname><given-names>Chin-Chun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-119427"><name><surname>Mendy</surname><given-names>Derek</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-119428"><name><surname>Jang</surname><given-names>In Sock</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-119429"><name><surname>Wang</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-119430"><name><surname>Marella</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-119431"><name><surname>Couto</surname><given-names>Suzana</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-119432"><name><surname>Cathers</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-119433"><name><surname>Carmichael</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" id="author-119434"><name><surname>Chamberlain</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf18"/></contrib><contrib contrib-type="author" id="author-119435"><name><surname>Rolfe</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf19"/></contrib><aff id="aff1"><institution content-type="dept">PH TCoE</institution>, <institution>Celgene</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Structral and Chemical Biology</institution>, <institution>Celgene</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Research Analytics</institution>, <institution>Celgene</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">NCD - Exploratory Toxicology</institution>, <institution>Celgene</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-4003"><name><surname>Harper</surname><given-names>Wade</given-names></name><role>Reviewing editor</role><aff><institution>Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>glu@celgene.com</email> (GL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>09</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e40958</elocation-id><history><date date-type="received"><day>10</day><month>08</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Lu et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Lu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-40958-v1.pdf"/><abstract><p>The cereblon modulating agents (CMs) including lenalidomide, pomalidomide and CC-220 repurpose the Cul4-RBX1-DDB1-CRBN (CRL4<sup>CRBN</sup>) E3 ubiquitin ligase complex to induce the degradation of specific neomorphic substrates via polyubiquitination in conjunction with E2 ubiquitin-conjugating enzymes, which have until now remained elusive. Here we show that the ubiquitin-conjugating enzymes UBE2G1 and UBE2D3 cooperatively promote the K48-linked polyubiquitination of CRL4<sup>CRBN</sup> neomorphic substrates via a sequential ubiquitination mechanism. Blockade of UBE2G1 diminishes the ubiquitination and degradation of neomorphic substrates, and consequent antitumor activities elicited by all tested CMs. For example, UBE2G1 inactivation significantly attenuated the degradation of myeloma survival factors IKZF1 and IKZF3 induced by lenalidomide and pomalidomide, hence conferring drug resistance. UBE2G1-deficient myeloma cells, however, remained sensitive to a more potent IKZF1/3 degrader CC-220. Collectively, it will be of fundamental interest to explore if loss of UBE2G1 activity is linked to clinical resistance to drugs that hijack the CRL4<sup>CRBN</sup> to eliminate disease-driving proteins.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Gang Lu, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf3"><p>Stephanie Weng, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf4"><p>Mary Matyskiela, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf5"><p>Xinde Zheng, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf6"><p>Wei Fang, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf7"><p>Scott Wood, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf8"><p>Christine Surka, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf9"><p>Reina Mizukoshi, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf10"><p>Chin-Chun Lu, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf11"><p>Derek Mendy, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf12"><p>In Sock Jang, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf13"><p>Kai Wang, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf14"><p>Mathieu Marella, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf15"><p>Suzana Couto, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf16"><p>Brian Cathers, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf17"><p>James Carmichael, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf18"><p>Philip Chamberlain, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf19"><p>Mark Rolfe, Employee of Celgene.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files</p></sec><supplementary-material><ext-link xlink:href="elife-40958-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>